Read by QxMD icon Read


Albert Nyongesa, Jemimah Oduma, Mustafa al'Absi, Sanika Chirwa
ETHNOPHARMACOLOGICAL RELEVANCE: Khat (Catha edulis) contains cathinone, an active principal that is customarily used as a psychostimulant that wards off fatigue and to some extent used as an aphrodisiac. AIM OF STUDY: To investigate effects of escalating doses of cathinone on hormone expression by different anterior pituitary cell types using specific antibodies. MATERIAL AND METHODS: Eleven vervet monkeys (6 males and 5 females) divided into tests (n=9) and controls (n=2) were used...
November 4, 2015: Journal of Ethnopharmacology
Stanislav Mikhailovich Pronin, Olga Valerievna Novikova, Julia Yurievna Andreeva, Elena Grigorievna Novikova
OBJECTIVE: To evaluate oncologic and reproductive outcome with levonorgestrel-releasing intrauterine system combined with gonadotropin-releasing hormone agonist in women with grade 1 endometrial carcinoma, and the levonorgestrel monotherapy in women with complex atypical hyperplasia. MATERIALS/METHODS: A prospective study was conducted. We analyzed the clinical characteristics of 70 patients younger than 42 years (mean age, 33 years) with a diagnosis of complex atypical endometrial hyperplasia (AEH) or grade 1 endometrial adenocarcinoma who were treated with hormonal therapy at the Division of Gynecologic Oncology of P...
July 2015: International Journal of Gynecological Cancer
L Wingate-Saul, J Rymer, M W Greaves
A 23-year-old, regularly menstruating woman presented with recurrent urticarial eruptions, which occurred premenstrually. A skin prick test was positive for progesterone, but the urticaria was unresponsive to standard treatments. The patient was treated with goserelin (Zoladex), which suppressed her menstrual cycle, leading to the resolution of her symptoms. Subsequent flares were controlled by further goserelin injections, and the urticaria is currently in remission. However, the risks of inducing menopause artificially are significant, and alternative long-term solutions may need to be considered in the event of a relapse...
August 2015: Clinical and Experimental Dermatology
Peng Lai, Ming Luo, Guanghui Hu, Huan Liu, Liang Xu, Zhuifeng Guo, Yunfei Xu
A 53-year-old man presented to our department with acute urinary retention and an approximate 8-year history of frequent urination, dysuria, poor urinary stream and nocturia. His prostate-specific antigen (PSA) values were normal (<4 ng/ml) upon repeated testing. The patient was diagnosed with benign prostatic hyperplasia, although there was no significant improvement in his symptoms after treatment with oral finasteride and doxazosin. He then underwent transurethral resection of the prostate in February 2013, and histopathological examination showed adenocarcinoma of the prostate...
August 16, 2014: Urologia Internationalis
O V Novikova, Iu Iu Andreeva, E G Novikova, A N Vostrov, S M Pronin, N A Rubtsova, N V Danilova, Iu A Lozovaia, D V Podtetenev
The results of conservative treatment of 121 patients with endometrial atypical hyperplasia (EAH) and early endometrial cancer (EC) with preservation of fertility are presented. In EAH (n = 56) for 6 months the intrauterine spiral Mirena was used. The effectiveness was 91%, the recurrence rate 16%, pregnancies occurred in 16% of patients. In EC (n = 65) hormone therapy was conducted for 6 months using the intrauterine spiral Mirena and zoladex. The effectiveness was 79%, recurrence rate 22%, pregnancies occurred in 24% of patients...
2014: Voprosy Onkologii
Hua-chun Luo, Li-ping Cheng, Hui-hua Cheng, Zhi-chao Fu, Shao-guang Liao, Dong-shi Li, Wen-fa Zheng, Gui-shan Lin, Jin-feng Zhu, Jian-feng Xu, Qin Yin, Qing-yang Yu
With great improvements in survival in patients with locally advanced prostate cancer, quality of life (QOL) is becoming an important factor in the selection of treatment. The aim of this study was to evaluate changes in health-related QOL in patients with locally advanced prostate cancer after intensity-modulated radiotherapy (IMRT) combined with androgen deprivation therapy. Patients were treated with IMRT combined with androgen deprivation. Total dose to the prostate was 68.2 Gy (2.2 Gy per fraction), and patients received 50 mg of oral Casodex once daily and 3...
June 2014: Medical Oncology
Lei Yuan, Qin-jiao Wu, Xi-shi Liu
OBJECTIVE: To evaluate the short-term effect of leuprorelin acetate microspheres in preventing recurrence of ovarian endometrioma after conservative surgery. METHODS: From January 2011 to September 2011, 190 ovarian endometrioma patients undergoing conservative laparoscopic surgery at Affiliated Obstetrics and Gynecology Hospital Affiliated to Fudan University were enrolled in this retrospective study. Among 184 patients were followed up, the range of following up were 12 to 21 months...
July 2013: Zhonghua Fu Chan Ke za Zhi
K Nirgianakis, N A Bersinger, B McKinnon, P Kostov, S Imboden, M D Mueller
OBJECTIVE: To investigate the effect of gonadotropin-releasing hormone analogues (GnRHa) on the peritoneal fluid microenvironment in women with endometriosis. STUDY DESIGN: Peritoneal fluid was collected from 85 women with severe endometriosis (rAFS stage III and IV) during laparoscopic surgery during the proliferative phase. Prior to surgery clinical data were collected. The concentrations of specific markers for endometriosis in the peritoneal fluid were determined using an ELISA and a comparison between peritoneal fluid markers in women using GnRHa and no hormonal treatment was performed using a non-parametric Mann-Whitney U test...
October 2013: European Journal of Obstetrics, Gynecology, and Reproductive Biology
M Wong, S O'Neill, G Walsh, I E Smith
BACKGROUND: Premature ovarian failure and infertility following chemotherapy in early breast cancer (EBC) are major concerns for young women. The role of gonadotrophin-releasing hormone (GnRH) agonists with chemotherapy in EBC in reducing the incidence of chemotherapy-induced early menopause remains uncertain, and long-term data on the recovery of fertility are sparse. We report an audit of our experience with the GnRH agonist, goserelin (Zoladex®), used with chemotherapy to preserve ovarian function and maintain fertility...
January 2013: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Tsui Fen Cheng, Jung Der Wang, Wu Ching Uen
BACKGROUND: Increased health care costs have made it incumbent on health-care facilities and physicians to demonstrate both clinical and cost efficacy when recommending treatments. Though studies have examined the cost-effectiveness of adjuvant goserelin with radiotherapy for locally advanced prostate cancer, few have compared the cost-effectiveness of adjuvant goserelin to adjuvant chemotherapy alone in premenopausal breast cancer. METHODS: In this retrospective study at one hospital, the records of 152 patients with stage Ia to IIIa ER + breast cancer who received goserelin or chemotherapy were reviewed...
2012: BMC Cancer
Asgerdur Sverrisdottir, Hemming Johansson, Ulla Johansson, Jonas Bergh, Samuel Rotstein, Larserik Rutqvist, Tommy Fornander
Ovarian ablation improves survival in premenopausal early breast cancer, but the potential added value by luteinizing hormone-releasing hormone (LHRH) agonists to tamoxifen is still not clear. The purpose of our study is to examine the efficacy of the LHRH agonist goserelin for adjuvant therapy of premenopausal breast cancer, the role of interaction between goserelin and tamoxifen and the impact of estrogen receptor (ER) content. A total of 927 patients were included in the Stockholm part of the Zoladex in Premenopausal Patients (ZIPP) trial...
August 2011: Breast Cancer Research and Treatment
Sheng Zhang, Chongjian Zhang, Jingjing Liu, Li Qin, Shude Cui, Jin Zhang
The purpose of this study was to evaluate the efficacy and safety of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in hormone-responsive, premenopausal, operable breast cancer. One hundred and nineteen patients with hormone-responsive, premenopausal, operable breast cancer were enrolled in the study. Zoladex at 3.6 mg was given by subcutaneous injection every 4 weeks for 3 cycles. CEF (cyclophosphamide, 600 mg/m(2), epirubicin, 60-90 mg/m(2), and fluorouracil 500 mg/m(2)) was administered every 3 weeks for 4 cycles as neoadjuvant therapy...
June 2012: Medical Oncology
Annemarie B Lüchinger, Velja Mijatovic, Thomas Rustemeyer, Peter G A Hompes
Anaphylactic reactions to gonadotropin-releasing hormone (GnRH) agonists are exceedingly rare, but if they occur, they can be life threatening. This case describes a 33-year-old patient with endometriosis who developed an acute allergic reaction on leuprolide (Lucrin) administration. Although skin tests with the replacement goserelin (Zoladex) were negative, usage of this medication resulted in a similar allergic reaction. This is the first case report that shows that, in case of a proven allergy to one GnRH agonist, a switch to another GnRH agonist should not be made even if allergy tests are negative for this medication...
March 2011: American Journal of the Medical Sciences
Hong-Yu Zhuang, Xue-Min Xu, Tao Peng, Chun-Ping Lin
OBJECTIVE: To evaluate the impact of neoadjuvant hormonal therapy on the permanent transperineal (125)I-seed brachytherapy for localized high-risk prostate cancer. METHODS: Ten patients with T(1)-T(2a) localized high-risk prostate cancer were reviewed. The mean level of PSA was (29.4 ± 12.6) µg/L (20 - 50 µg/L) and the mean prostate volume (54 ± 33) ml. All cases were sequentially treated on a neoadjuvant hormonal therapy with 1 week of Casodex (50 mg/d) and 3 - 10 months (median: 6 months) of Casodex (50 mg/d) with Zoladex (3...
December 28, 2010: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Norikazu Masuda, Hiraji Iwata, Yoshiaki Rai, Keisei Anan, Toru Takeuchi, Norio Kohno, Hiroyuki Takei, Yasuhiro Yanagita, Shinzaburo Noguchi
This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-inferiority analysis (10.8/3.6 mg) of the area under the concentration-time curve (AUC) of estradiol (E(2)) over the first 24 weeks. Secondary endpoints included E(2) and follicle-stimulating hormone (FSH) concentrations, menstruation, and safety and tolerability...
April 2011: Breast Cancer Research and Treatment
Yesim Bayoglu Tekin, Berna Dilbaz, Sadiman Kiykac Altinbas, Serdar Dilbaz
OBJECTIVE: To compare efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) with depot GnRH analogue (GnRH-a; gosareline acetate; Zoladex) on endometriosis-related chronic pelvic pain (CPP) in patients with severe endometriosis during 12 months. DESIGN: Prospective, randomized, controlled study. SETTING: The reproductive endocrinology unit of a tertiary, research and education hospital. PATIENT(S): Forty women with severe endometriosis (revised The American Fertility Society [AFS] classification >40) and endometriosis-related CPP and control groups were enrolled in the study...
February 2011: Fertility and Sterility
S Ivanov, E Kovachev, A Tsonev, A Abbud
AIM: Our aim was to summarize our and foreign experience in the field of diagnosis, progression and modern treatment of precancer of the endometrium-the atypical glandular hyperplasia. MATERIAL AND METHODS: We researched 750 cases with glandular and atypical glandular hyperplasia for 10 years period (2000-2010). The hyperplasia were followed up for progression from glandular hyperplasia into atypical glandular hyperplasia and early endometrial cancer. The hyperplasias were evaluated with or without progestagen hormonal therapy...
2010: Akusherstvo i Ginekologii︠a︡
Jason P Mansell
Scant attention has been paid to the potential role of gonadotropins in bone tissue homeostasis. The focus on estrogen and estrogen replacement therapy for osteoporosis as far back as the 1940's may account for the paucity of gonadotropin studies in bone biology. It is conceivable that prevailing dogma may have subconsciously steered us away from addressing whether gonadotropins have a place in skeletal physiology. However an examination of bone tissue catabolism in ovariectomized (OVX) and luteinizing hormone-releasing hormone (LHRH) agonist (Zoladex((R)))-treated rats generated some interesting and conflicting data; Zoladex-treated rats, unlike the OVX group, failed to exhibit increased bone collagen catabolism despite clear evidence for estrogen deficiency...
November 30, 2008: International Journal of General Medicine
M Al-Azemi, G Jones, F Sirkeci, S Walters, M Houdmont, W Ledger
OBJECTIVE: To assess the safety and efficacy of long-term use of long-acting GnRH agonist in women with chronic cyclical pelvic pain using immediate versus delayed add-back hormonal replacement therapy (HRT). DESIGN: A prospective randomised trial. SETTING: Reproductive and Developmental Medicine, Academic Unit, University Teaching Hospital and NHS Hospitals. POPULATION: Thirty-eight premenopausal women with chronic cyclical pelvic pain were recruited...
November 2009: BJOG: An International Journal of Obstetrics and Gynaecology
Allan Hackshaw, Michael Baum, Tommy Fornander, Bo Nordenskjold, Antonio Nicolucci, Kathryn Monson, Sharon Forsyth, Krystyna Reczko, Ulla Johansson, Helena Fohlin, Miriam Valentini, Richard Sainsbury
BACKGROUND: Systematic reviews have found that luteinizing hormone-releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer. METHODS: We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years. Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy)...
March 4, 2009: Journal of the National Cancer Institute
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"